Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 6, 1996, Pages 746-754

  Duncan, Ann Maree ^a   Burrell, Louise M ^b   Kladis, Athena ^a   Campbell, Duncan J ^a  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

Angiotensin; Angiotensin converting enzyme inhibition; Bradykinin; Cardiac failure; Myocardial infarction

Indexed keywords

ANGIOTENSIN; BRADYKININ DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; DRUG EFFECT; HEART INFARCTION; HEART VENTRICLE REMODELING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE LEVEL;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; BRADYKININ; HEART; INDOLES; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; ORGAN SIZE; PERINDOPRIL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0029820696     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199612000-00003     Document Type: Article

References (47)

1. Cohn JN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation 1995;91:2504-7.
2. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1981;316:1429-35.
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
4. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G, for the meeting participants. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation 1995;92:3132-7.
5. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985;72:406-12.
6. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84-95.
7. Schieffer B, Wirger A, Meybrunn M, et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;89:2273-82.
8. Sanbe A, Takeo S. Long-term treatment with angiotensin I-converting enzyme inhibitors attenuates the loss of cardiac β-adrenoceptor responses in rats with chronic heart failure. Circulation 1995;92:2666-75.
9. Van Krimpen C, Smits JFM, Cleutjens JPM, et al. DNA synthesis in the non-infarcted cardiac interstitium after left coronary artery ligation in the rat: effects of captopril. J Mol Cell Cardiol 1991;23:1245-53.
10. Raya TE, Gay RG, Aguirre M, Goldman S. Importance of venodilatation in prevention of left ventricular dilatation after chronic large myocardial infarction in rats: a comparison of captopril and hydralazine. Circ Res 1989;64:330-7.
11. Gaballa MA, Raya TE, Goldman S. Large artery remodeling after myocardial infarction. Am J Physiol 1995;268:H2092-103.
12. Mulder P, Devaux B, El Fertak L, et al. Vascular and myocardial protective effects of converting enzyme inhibition in experimental heart failure. Am J Cardiol 1995;76:28E-33E.
13. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation 1993;87(suppl VI):VI-40-8.
14. Campbell DJ, Kladis A, Duncan A-M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994;23:439-49.
15. Crawford DC, Chobanian AV, Brecher P. Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ Res 1994;74:727-39.
16. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993;75:977-84.
17. 1 receptor subtype. Circ Res 1993;73:413-23.
18. Yamazaki T, Komuro I, Kudoh S, et al. Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. Circ Res 1995;77:258-65.
19. Schunkert H, Sadoshima J, Cornelius T, et al. Angiotensin II-induced growth responses in isolated adult rat hearts: evidence for load-independent induction of cardiac protein synthesis by angiotensin II. Circ Res 1995;76:489-97.
20. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25-49.
21. Martorana PA, Kettenbach B, Breipohl G, Linz W, Schölkens BA. Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 1990;182:395-6.
22. McDonald KM, Mock J, D'Aloia A, et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995;91:2043-8.
23. Hodsman GP, Kohzuki M, Howes LG, Sumithran E, Tsunoda K, Johnston CI. Neurohumoral responses to chronic myocardial infarction in rats. Circulation 1988;78:376-81.
24. Campbell DJ, Kladis A, Duncan A-M. Nephrectomy, converting enzyme inhibition and angiotensin peptides. Hypertension 1993;22:513-22.
25. Campbell DJ, Rong P, Kladis A, Rees B, Skinner SL. Angiotensin and bradykinin peptides in the TGR(mRen-2)27 rat. Hypertension 1995;25:1014-20.
26. Campbell DJ, Lawrence AC, Kladis A, Duncan A-M. Strategies for measurement of angiotensin and bradykinin peptides and their metabolites in central nervous system and other tissues. In: Smith AI, ed. Methods in neurosciences, vol 23: peptidases and neuropeptide processing. Orlando: Academic Press, 1995:328-43.
27. Campbell DJ, Kladis A, Duncan A-M. Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension 1993;21:155-65.
28. Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentijn AJ. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 1991;18:763-73.
29. Johansen KB, Marstein S, Aas P. Automated method for the determination of angiotensin-converting enzyme in serum. Scand J Clin Lab Invest 1987;47:411-4.
30. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cardiol 1993;25:1369-80.
31. Fabris B, Jackson B, Kohzuki M, Perich R, Johnston CI. Increased cardiac angiotensin-converting enzyme in rats with chronic heart failure. Clin Exp Pharmacol Physiol 1990;17:309-14.
32. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991;69:475-82.
33. Sun Y, Cleutjens JPM, Diaz-Arias AA, Weber KT. Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. Cardiovasc Res 1994;28:1423-32.
34. Falkenhahn M, Franke F, Bohle RM, et al. Cellular distribution of angiotensin-converting enzyme after myocardial infarction. Hypertension 1995;25:219-26.
35. Passier RCJJ, Smits JFM, Verluyten MJA, Studer R, Drexler H, Daemen MJAP. Activation of angiotensin-converting enzyme expression in infarct zone following myocardial infarction. Am J Physiol 1995;269:H1268-76.
36. Drexler H, Lindpaintner K, Lu W, Schieffer B, Ganten D. Transient increase in the expression of cardiac angiotensinogen in a rat model of myocardial infarction and failure [Abstract]. Circulation 1989;80(suppl II):II-459.
37. Meggs LG, Coupet J, Huang H, et al. Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ Res 1993;72:1149-62.
38. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 1995;95:46-54.
39. 1 receptor. Am J Hypertens 1992;5:276-80.
40. Helin K, Tikkanen I, Hohenthal U, Fyhrquist F. Inhibition of either angiotensin-converting enzyme or neutral endopeptidase induces both enzymes. Eur J Pharmacol 1994;264:135-41.
41. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 1993;21:996-1003.
42. Ehring T, Baumgart D, Krajcar M, Hümmelgen M, Kompa S, Heusch G. Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide. Circulation 1994;90:1368-85.
43. Kojima M, Shiojima I, Yamazaki T, et al. Angiotensin 11 receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation 1994;89:2204-11.
44. Raya TE, Fonken SJ, Lee RW, et al. Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure. Am J Hypertens 1991;4(suppl):334S-40S.
45. Nishikimi T, Yamagishi H, Takeuchi K, Takeda T. An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat. Cardiovasc Res 1995;29:856-61.
46. 2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992;105:771-2.
47. Sun Y, Ratajska A, Weber KT. Bradykinin receptor and tissue ACE binding in myocardial fibrosis: response to chronic angiotensin II or aldosterone administration in rats. J Mol Cell Cardiol 1995;27:813-22.